摘要
目的探讨帕罗西汀联合奥氮平对躯体形式障碍的疗效。方法将167例躯体形式障碍患者随机分为研究组和对照组,研究组即帕罗西汀联合奥氮平组,对照组为单用帕罗西汀组,治疗前后应用抑郁自评量表(SDS)和副反应量表(TESS)分别评定疗效及不良反应。结果治疗第2周末,研究组SDS评分较治疗前有显著性降低(P<0.05),而对照组无显著性变化。治疗第4周末及第8周末,两组SDS评分较治疗前均有显著性降低(P<0.05)。在第2周末及第4周末,研究组和对照组的治疗有效率有显著性差异(P<0.05)。两组均未出现严重不良反应。结论帕罗西汀联合奥氮平治疗躯体形式障碍较单用帕罗西汀,具有疗效好,起效快,不良反应少的优点。
Objective To explore the efficacy of paroxetine augmented with olanzapine in treatment of somatoform disorder. Methods A total of 167 patients with somatoform disorder were randomly divided into study group with paroxetine augmented with oalanzapine and control group with paroxetine for the treatment of 8 weeks. They were assessed using Self-Rating Depression Scale （SDS） and Treatment Emergent Side Effect Scale（TESS） . Results In the 2nd weekend, the scores of SDS in study group were significantly lower than those before treatment（P〈0.05） and there was no difference in control group（P〉0.05）. In the 4th and 8th weekend, the scores of SDS significantly decreased of SDS both in study group and control group（P〈0.05）. The effective rates had significant differences between two groups in the 2nd and 4th weekend（P〈0. 05）. No severe side effects were found in study group and control group. Conclusion Paroxetine augmented with olanzapine in the treatment of somatoform disorder takes effects better and faster than single paroxetine and has fewer tincrease side effects.
出处
《精神医学杂志》
2007年第6期360-361,共2页
Journal of Psychiatry
